Artiva Biotherapeutics (NASDAQ:ARTV) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a research report released on Tuesday,Benzinga reports. Needham & Company LLC currently has a $23.00 target price on the stock.

Separately, HC Wainwright started coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $20.40.

Artiva Biotherapeutics Trading Up 2.0 %

NASDAQ:ARTV opened at $3.99 on Tuesday. The company’s 50-day moving average is $4.91 and its two-hundred day moving average is $9.37. Artiva Biotherapeutics has a 1-year low of $3.37 and a 1-year high of $17.31.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $42,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Artiva Biotherapeutics during the fourth quarter worth $52,000. Wells Fargo & Company MN grew its stake in shares of Artiva Biotherapeutics by 64.0% in the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after buying an additional 3,361 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at $135,000. Finally, JPMorgan Chase & Co. acquired a new position in Artiva Biotherapeutics during the 3rd quarter worth about $166,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.